ZPL389 30mg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Atopic Dermatitis

Phase 2

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

TerminatedNCT03517566

Novartis PharmaceuticalsAtopic Dermatitis

Start: 2018-11-14End: 2020-08-06Updated: 2021-10-08

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

TerminatedNCT03948334

Novartis PharmaceuticalsAtopic Dermatitis

Start: 2019-04-04End: 2020-08-25Updated: 2021-10-08